The non-steroidal anti-inflammatory drug, Tolfenamic acid (TA) acts as an anti-cancer agent in several adult and pediatric cancer models. Copper (Cu) is an important element with multiple biological functions and has gained interest in medical applications. Recently, [Cu(TA) 2 (bpy)] (Cu-TA) has been synthesized in order to enhance therapeutic activity. In this study, we synthesized Cu-TA using an established method, characterized it by UV visible spectroscopy and Fourier-transform infrared spectroscopy (FTIR), and tested its anti-cancer activity using twelve cell lines representing various cancers, such as Ewing sarcoma, glioblastoma, medulloblastoma, neuroblastoma, pancreatic and prostate. The anti-proliferative activity of Cu-TA was determined at 48 h post-treatment and compared with the parental compound, TA. The IC 50 values were calculated using GraphPad Prism software. The biological stability of Cu-TA was evaluated using twelve-month-old powder and six-month-old stock solution. Cardiomyocytes (H9C2) were used to test the cytotoxicity in non-malignant cells. Cu-TA showed higher anti-proliferative activity, and the IC 50 values were 30 to 80% lower when compared with TA. H9C2 cells were non-responsive to Cu-TA, suggesting that it is selective towards malignant cells. Comparison of the twelve-month-old powder and six-month-old stock solution using the Panc1 cell line showed similar IC 50 values (<5% variation), confirming the stability of Cu-TA either in powder or solution form. These findings demonstrate the potential of Cu-TA as an effective anti-cancer agent. Further studies to delineate the detailed mechanism of action of Cu-TA for specific cancer model are underway.
Introduction
Metals are known to play a crucial role in the sustainability of life, and the homeostasis of metals is important for maintaining good health. Particularly, the essential metals critically involved in multiple biological functions and their use in medical benefits have been explored for a longtime [1, 2] . Even non-essential metals show medical benefits and are used in some medicines. For example, platinum (Pt)-based drugs such as cisplatin and carboplatin are routinely used in cancer treatment [3] [4] [5] [6] [7] . Copper (Cu) is a transition element and an essential metal that plays a critical role in biological functions such as growth, respiration and metabolism [1, 2] . The medical use of Cu has gained substantial interest, resulting in thousands of publications covering several diseases. Copper-containing compounds have been tested for their ability to potentiate the therapeutic response of certain medicines, and this work has led to a strategy for testing Cu-based drugs. Subsequently, Cu complexes were tested in pre-clinical studies using cancer models including in targeted delivery [8] [9] [10] .
Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly being examined for cancer prevention and treatment (either alone or with chemo or radiation therapy) using various cancer models. NSAIDs are not only effective, but less toxic than conventional chemotherapy drugs [11, 12] . However, there is insufficient clinical evidence to replace current standard care consisting of chemotherapy and/or radiation with NSAIDs or other small molecules. Other limitations of using NSAIDs in cancer therapy are morbidities associated with long-term use of COX inhibitors [13, 14] . Extended use of COX-1 inhibitors can cause gastrointestinal issues, while COX-2 inhibitors can increase the incidence of cardiovascular events. Therefore, there is a rising interest in finding NSAIDs that work in mechanisms independent of COX inhibition.
Tolfenamic acid (TA) is an NSAID and is used as a generic drug for treating migraine headaches in Europe. Studies from our group and others demonstrate that TA contains anti-cancer properties, such as inhibition of cancer cell and tumor growth in pre-clinical models. TA works through downregulation of transcription factors, Specific proteins 1 and 3 (Sp1 and Sp3), and an inhibitor of apoptosis protein, baculoviral inhibitor of apoptosis repeat-containing 5 (survivin). Sp1, Sp3 and survivin are found to be over-expressed in several cancers and associated with aggressive disease and its resistance to standard treatment options [15] [16] [17] [18] [19] . Importantly, TA was approved for Phase I clinical trials alongside gemcitabine and radiation for pancreatic cancer.
Metal complexes in metallodrugs have a synergistic activity that optimizes the parent drug's bioactivity [20, 21] . Recently, metal complexes of NSAIDs were shown to be more effective compared with regular NSAIDs [22] . The Copper(II)-Tolfenamic acid (Cu-TA) complex was synthesized and found to contain a higher antioxidant activity compared to TA [23] ; however, its anti-cancer activity needs further study. The objective of this investigation is to determine the effectiveness of Cu-TA for inducing anti-proliferative activity in cancer cells. In this screening study, we have used twelve cells lines representing six malignancies that affects children, adolescent/young adults and adults. The selected cancers are, Ewing sarcoma, glioblastoma, medulloblastoma, neuroblastoma, pancreatic and prostate cancers. The data presented in this study includes the characterization and biological stability testing of the compound as well as the assessment of anti-proliferative activity against cancer cells and cardiomyocytes (non-malignant cells). The possible mechanisms associated with this compound, as determined from existing literature, are also schematically emphasized.
Methods

Characterization of Cu-TA
The Cu-TA complex [Cu(TA) 2 (bpy)] was prepared following published methodology (bpy -2,2'-bipyridine) [23] . Then, the complex was characterized using UV-visible and FTIR spectroscopic techniques. Bruker Platinum ATR-IR spectrometer was used for FTIR spectroscopy, and the UV-visible spectrum was acquired using an Agilent HP8453 diode array spectrophotometer [24] . Using the FTIR spectrum, the two important stretching frequencies were observed at 1579 cm −1 and 1385 cm −1 for CO 2 (asym) and CO 2 (sym), respectively for the coordinated carboxlate anion of TA. In the UV-visible spectrum (with DMSO as a solvent), the λ max was observed at 680 nm, which was assigned as a d-d transition due to the presence of the Cu(II) metal center.
Preparation of stock concentrations
TA and Cu-TA were dissolved in dimethyl sulfoxide (DMSO), and 10-mM stock solutions were prepared. For dose curves, serial dilutions were made in cell culture media corresponding to each cell line.
Cell lines and culture conditions
Twelve human cancer cells lines representing 6 diseases were used in this study. 
Cell viability
Selected cell lines were seeded in 96-well plates; each well contained 4000 cells, except DAOY cells. For DAOY (due to itslarger size), only 2000 cells/well were seeded. Cells were treated with DMSO (vehicle) for the control or increasing concentrations of TA (5/10/25/50/100 μM) or Cu-TA (5/10/ 25/50 μM). After 48 h post treatment, cells were incubated with CellTiter-Glo reagent in the dark for 20 min. Then, the cell viability was measured by detecting luminescence using the Synergy HT (BioTek) plate reader [19, 25] .
Statistical analysis
Results were expressed as mean ± SD. Data were statistically analyzed (one-way ANOVA) and the significance between treated and untreated cells were evaluated. Samples with pvalues <0.05 were considered significant.
Results
Characterization and stability of Cu-TA complex Physical characterization and stability of Cu-TA was performed using FTIR and UV-visible spectroscopies. Both spectra were obtained with the freshly prepared Cu-TA powder and 8 months later. As shown in Fig. 1 Assessing the stability of Cu-TA in anti-proliferative activity Biological activity testing of the Cu-TA complex was performed using the 6-month-old and one-year-old Cu-TA using pancreatic cancer cells, Panc1. Dose curves were repeated using 12-month-old Cu-TA powder and 6-month-old solution. the IC 50 values were found to be within the margin of error (<5% variation). These results confirm stability in the biological activity of the compound (Fig. 4a&b) .
Effect of Cu-TA against non-malignant cells To determine the effect of Cu-TA against non-cancerous cells, we evaluated the cytotoxicity of the compound on cardiomyocytes, H9C2. Cells were treated with increasing dosages of TA or Cu-TA, and cell viability was measured at 24 and 48 h (Fig. 4c ). H9C2 cells growth was not affected by Cu-TA, suggesting that Cu-TA is not toxic against cardiomyocytes.
Discussion
Cancer treatment involves cytotoxic agents that often cause severe side-effects. Even though the outcomes of cancer patients have tremendously improved over the past decades, prognoses of certain types of cancers (e.g., glioblastoma, pancreatic cancer) are still extremely low. Therefore, identifying new investigational agents with anti-cancer activity and low toxic effects on normal/healthy cells is extremely important. Recently, preclinical studies demonstrate significant progress in identifying small molecules, such as NSAIDs, to use in cancer treatment. TA is an NSAID which was tested in multiple cancer models by many research groups. In addition, TA was approved for use in Phase I clinical trials with pancreatic cancer patients (in conjunction with gemcitabine/radiation). Even though TA is a relatively safer NSAID, its IC 50 values may elicit concerns in certain cancer models. Therefore, the objective of this study was to test Cu-TA for enhanced anti-cancer activity. The Cu-TA was successfully synthesized using an established protocol [23] and characterized to ascertain structural confirmation. The physical characterization of the Cu-TA complex was performed again after 8 months, and both results were found to be consistent as evaluated by their FTIR and UV visible spectra. Importantly, the anti-cancer activity of Cu-TA in its powder form was retained through 12 months after synthesis. Therefore, the Cu-TA complex is physically and biologically stable for at least a year. Cu-TA had significantly greater activity against different cancer cell growth than TA. The anti-proliferative activity of Cu-TA was evaluated using twelve cancer cell lines. The cancer cell lines for this study were selected representing the cancers that are diagnosed in children (medulloblastoma and neuroblastoma), adolescent and young adults (Ewing sarcoma) and adults (glioblastoma, pancreatic and prostate). Cu-TA caused growth inhibition in all cancer cell lines and showed a significantly higher response when compared with TA. The IC 50 values for some cancer cell lines (e.g., glioblastoma, medulloblastoma, neuroblastoma) were > 70% lower than TA. Even though we cannot think of any similarity among these cell lines, it seems that multiple mechanisms could be associated with such a response (Fig. 5) . Cu possesses pro-oxidant activity and induces reactive oxygen species, which leads to cytotoxicity [26] . Cu (II) ions are known to cause cytotoxicity The potential mechanisms that may cause the anti-cancer activity of Cu-TA: Exploring the published work on Cu(II)-containing products in cancer, it is postulated that multiple mechanisms could be associated with the anti-cancer activity of Cu-TA. For example, induction of Reactive Oxygen Species (ROS), chelating effect disrupting the DNAbinding, immunomodulation (eg., cytokines) can induce apoptosis. Cu compounds are also known to suppress the activity of mutated p53. Inhibition of Sp1, Sp3 and survivin can cause both induction of apoptosis and cell cycle arrest, while the direct/in-direct effect on cyclins and/or cyclin-dependent kinases can lead to cell cycle arrest ultimately leading to cell death or growth inhibition in cancer cells by interfering with iron-sulfur clusters in proteins and conformational changes in metallo-proteins by displacing metals such as Zinc [27] [28] [29] . Copper(II) complexes with the ligands such as bis(thiosemicarbazone) were tested in several cancer models [30] [31] [32] , while CuII(gtsm) [glyoxalbis(N4methylthiosemicarbazonato)CuII] was very effective at reducing cancer burden and lesion grade in an animal model (TRAMP) for prostate cancer [26] . Zhang et al. demonstrated that copper (II) complexe (3-indolecarboxylic acid) targets the 20S proteasome at the β5 subunit and cause the deactivation of the proteasome in cancer cells as well as anti-cancer activity [33] . (II)-containing species are believed to act as antiinflammatory agents [31, [34] [35] [36] by modulating the synthesis of prostaglandins [37] [38] [39] . TA is known to inhibit Sp1, Sp3 and survivin, and these properties may be either retained or even improved with Cu-TA. These proteins participate in multiple impactful activities that can induce apoptosis and/or cell cycle arrest. Cu(II)-containing products can also exhibit immunomodulatory responses that affect the expression of cytokines (e.g., interleukin IL-2) [40] . Thus, the addition of Cu enhances the cytotoxic activity of TA against cancer cell proliferation.
Neither TA nor Cu-TA caused any significant cytotoxicity in non-malignant H9C2 cells. These results are very crucial and confirm that the anti-proliferative activity of Cu-TA is not an obvious effect against all cells. NSAIDs are known to induce cardiotoxicity, and these results showed no toxicity in cardiomyocytes. This suggests that this compound is relatively safe; however, further experiments using more nonmalignant cells and animal studies are required to confirm the safety of Cu-TA.
Formation of stable metal NSAIDs with anti-cancer activity is a challenge, and several compounds were made and tested with little to moderate success due to limitations in stability, specificity and consistent biological (anti-cancer) activity. This investigation demonstrates the preparation of a Cu-TA complex with long-term stability in physical structure and activity. Interestingly, Cu-TA was more effective than its parent compound against all tested cancer cell lines; in particular, it exhibited significantly higher anti-proliferative activity with 50-80% decrease in the IC 50 values. Further experiments are underway using cancer models to precisely understand the underlying mechanisms of action of this compound. 
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